Alpha 2.0
Login Register
» Authors » Sundar Neelakantan

Sundar Neelakantan

Explore the profile of Sundar Neelakantan including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 451
Followers 0
Related Specialties
Biochemistry
Hematology
General Surgery
Top 10 Co-Authors
Peter A Crooks
Christopher J Sweeney
Harikrishna Nakshatri
C Max Schmidt
Peter Crooks
Matthew Ralstin
Monica L Guzman
Huangbing Wu
William Matthews
Craig T Jordan
Published In
Bioorg Med Chem Lett
Blood
Biochemistry
J Surg Res
Acta Crystallogr Sect E Struct Rep Online
Affiliations
Soon will be listed here.
Recent Articles
1.
(11R)-13-Dimethyl-ammonio-11,13-dihydro-4,5-epoxy-costunolide semifumarate
Neelakantan S, Parkin S, Crooks P
Acta Crystallogr Sect E Struct Rep Online . 2011 May; 65(Pt 7):o1569. PMID: 21582849
Crystals of the title salt, C(17)H(28)NO(3) (+)·C(4)H(3)O(4) (-), were obtained by reacting parthenolide with dimethyl-amine followed by conversion of the amine adduct into a water-soluble fumarate salt. Subsequent crystallization of...
2.
A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species
Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, et al.
Int J Cancer . 2010 Jul; 128(10):2481-94. PMID: 20669221
Dimethylaminoparthenolide (DMAPT) is a water soluble parthenolide analog with preclinical activity in hematologic malignancies. Using non-small lung cancer (NSCLC) cell lines (A549 and H522) and an immortalized human bronchial epithelial...
3.
A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species
Shanmugam R, Kusumanchi P, Cheng L, Crooks P, Neelakantan S, Matthews W, et al.
Prostate . 2010 Mar; 70(10):1074-86. PMID: 20209491
Background: To characterize the molecular changes associated with DMAPT-induced prostate cancer cell death and its in vivo activity. Methods: CWR22Rv1 and PC-3 were subjected to flow cytometry, electrophoretic mobility shift...
4.
Synthesis of novel isoluminol probes and their use in rapid bacterial assays
Neelakantan S, Surjawan I, Karacelik H, Hicks C, Crooks P
Bioorg Med Chem Lett . 2009 Aug; 19(19):5722-6. PMID: 19700327
Rapid assays for bacteria have been developed utilizing novel LysLysLys-isoluminol (14) and GluGlu-isoluminol (16) probes that have been derived from peptides which potentially mimic bacteriophage attachment protein binding regions. Compared...
5.
Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1)
Neelakantan S, Nasim S, Guzman M, Jordan C, Crooks P
Bioorg Med Chem Lett . 2009 Jun; 19(15):4346-9. PMID: 19505822
A series of aminoparthenolide analogs (6-37) were synthesized and evaluated for their anti-leukemic activity. Eight compounds exhibited good anti-leukemic activity with LD(50)'s in the low microM range (1.5-3.0microM). Compounds 16,...
6.
Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia
Jenkins C, Hewamana S, Gilkes A, Neelakantan S, Crooks P, Mills K, et al.
Br J Haematol . 2008 Nov; 143(5):661-71. PMID: 19036014
Nuclear factor-kappaB (NF-kappaB) has been implicated in a number of malignancies and has been suggested to be a potential molecular target in the treatment of leukaemia. This study demonstrated the...
7.
Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer
Yip-Schneider M, Wu H, Njoku V, Ralstin M, Holcomb B, Crooks P, et al.
Pancreas . 2008 Sep; 37(3):e45-53. PMID: 18815538
Objectives: Cancer of the exocrine pancreas is the fourth leading cause of cancer-related deaths in the United States. The efficacy of a novel bioavailable anticancer agent, dimethylamino-parthenolide (DMAPT), and the...
8.
The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
Hewamana S, Alghazal S, Lin T, Clement M, Jenkins C, Guzman M, et al.
Blood . 2008 Jan; 111(9):4681-9. PMID: 18227347
In this study, we characterized nuclear factor kappaB (NF-kappaB) subunit DNA binding in chronic lymphocytic leukemia (CLL) samples and demonstrated heterogeneity in basal and inducible NF-kappaB. However, all cases showed...
9.
Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer
Vegeler R, Yip-Schneider M, Ralstin M, Wu H, Crooks P, Neelakantan S, et al.
J Surg Res . 2007 Oct; 143(1):169-76. PMID: 17950089
Background: Lung cancer is the leading cause of cancer deaths in the United States. Inflammatory molecules, cyclooxygenase-2 (COX-2) and nuclear factor kappa B (NF-kappaB) have been implicated in lung carcinogenesis....
10.
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
Guzman M, Rossi R, Neelakantan S, Li X, Corbett C, Hassane D, et al.
Blood . 2007 Sep; 110(13):4427-35. PMID: 17804695
Leukemia stem cells (LSCs) are thought to play a central role in the pathogenesis of acute leukemia and likely contribute to both disease initiation and relapse. Therefore, identification of agents...